Table 3. Multivariate Cox model analysis in patients included in the prospective analysis (n = 190).

All Patients (n = 190)
	Progression- free survival (PFS)		Cancer-specific survival (CSS)
	HR (95% CI)	p value	HR (95% CI)	p value
Sex	1.02 (0.39–2.61)	0.976	1.76 (0.72–4.30)	0.217
Tumor size (T)	2.18 (1.29–3.70)	0.004	1.78 (0.99–3.18)	0.050
Node (N)	1.88 (1.13–3.16)	0.016	2.23 (1.22–4.07)	0.009
Age	0.86 (0.54–1.37)	0.514	0.767 (0.46–1.29)	0.320
SERPINE1	1.73 (1.02–2.92)	0.042	1.78 (0.98–3.23)	0.057

Radiotherapy/Chemoradiotherapy treated (n = 131)
	Progression- free survival (PFS)		Cancer-specific survival (CSS)
	HR (95% CI)	p value	HR (95% CI)	p value
Sex	1.13 (0.39–3.29)	0.976	1.76 (0.58–5.30)	0.317
Tumor size (T)	2.39 (1.29–4.39)	0.005	1.95 (0.97–3.89)	0.059
Node (N)	1.71 (0.94–3.11)	0.077	2.41 (1.15–5.06)	0.020
Age	0.83 (0.48–1.44)	0.507	0.84 (0.443–1.59)	0.594
SERPINE1	1.92 (1.03–3.59)	0.043	1.80 (0.86–3.78)	0.117

Sex = Male versus Female; Tumor size = T3-T4 versus T1-T2; Node (N) = positive node versus negative node; Age: < 60 years versus > 60 years; SERPINE1 = high versus low expression

HR = Hazard Ratio; 95% IC = 95% Confidence Interval;